耐药结核病化学治疗研究的过去、现状与未来

doi:10.3969/j.issn.1000-6621.2014.08.003

中国防痨杂志 ›› 2014, Vol. 36 ›› Issue (8): 634-637.doi: 10.3969/j.issn.1000-6621.2014.08.003

耐药结核病化学治疗研究的过去、现状与未来

肖和平方勇范琳刘一典

200433 同济大学附属上海市肺科医院结核病诊疗中心上海市结核病（肺）重点实验室

收稿日期:2014-07-08 出版日期:2014-08-10 发布日期:2014-09-07
通信作者: 肖和平 E-mail:xiaoheping_sars@163.com

The past, present and future of study in the chemotherapy of drug-resistant tuberculosis

XIAO He-ping, FANG Yong, FAN Lin, LIU Yi-dian

Shanghai Key Lab of Tuberculosis, Tuberculosis Center for Diagnosis and Treatment, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China

Received:2014-07-08 Online:2014-08-10 Published:2014-09-07
Contact: XIAO He-ping E-mail:xiaoheping_sars@163.com

摘要/Abstract

摘要： 耐药结核病的流行是当前结核病控制工作面临的主要挑战之一，严重威胁人们在结核病控制领域所取得的成就。抗结核药物是控制结核病的最有效武器，但面对耐多药结核病尤其是广泛耐药结核病明显力不从心，结核病有可能因此而再度成为“不治之症”。研制更有效的抗结核药物，设计具有抗耐药结核病的化学治疗方案，化解耐药结核病的治疗困境，迫在眉睫。作者通过回顾历史，着眼现在，展望未来，阐述耐药结核病化学治疗的若干问题，期待有助于读者对耐药结核病化学治疗研究有一个较为全面的认识，共同探索化学治疗控制耐药结核病流行的可行性。

关键词: 结核, 抗多种药物性/药物疗法, 临床方案, 回顾性研究

Abstract: The prevalence of drug-resistant tuberculosis (TB) is one of the main challenges on current TB control which seriously influences the achievement people had made in this field. Anti-TB drugs are the most effective weapons in controlling TB, however, they have been obviously not enough to deal with multidrug-resistant TB, especially extensively drug-resistant TB, TB is more likely to become the incurable disease again because of this reason. Therefore, it is urgent to develop more effective anti-TB drugs, design the chemotherapy regiment on drug-resistant TB and solve the difficulty in treating drug-resistant TB. The authors reviewed the history, focused on the present and looked ahead the future, elucidated several issues about treatment on drug-resistant TB and had expectation that readers would have a comprehensively understanding of chemotherapy for drug-resistant TB and make efforts altogether to explore the possibility of controlling the epidemic of drug-resistant TB by chemotherapy.

Key words: Tuberculosis, multidrug-resistant/drug therapy, Clinical protocols, Retrospective studies

肖和平，方勇，范琳，刘一典. 耐药结核病化学治疗研究的过去、现状与未来[J]. 中国防痨杂志, 2014, 36(8): 634-637. doi: 10.3969/j.issn.1000-6621.2014.08.003

XIAO He-ping, FANG Yong, FAN Lin, LIU Yi-dian. The past, present and future of study in the chemotherapy of drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2014, 36(8): 634-637. doi: 10.3969/j.issn.1000-6621.2014.08.003

参考文献

［1］Grosset J.The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.Bull Int Union Tuberc, 1978，53(1):5-12.
［2］［No authors listed］.Controlled clinieal trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet,1974, 2(7875):237-240.
［3］World Health Organization.Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva:World Health Organization,1996.
［4］World Health Organization．Global tuberculosis report 2013. Geneva：World Health Organization，2013．
［5］Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect of pyrazinamide and ofloxacin within the human macrophage.Tuber Lung Dis, 1996, 77(6):491-495.
［6］中国防痨协会. 耐多药结核病化学治疗的意见(试行). 中国防痨杂志，2003，25 (1)：4-9.
［7］中国防痨协会. 耐多药结核病化学治疗指南（2009）.中国防痨杂志，2010，32（4）：181-198.
［8］World Health Organization. Guidelines for the programmaticmanagement of drug-resistant tuberculosis. 2011 update.WHO/HTM/TB/2011.6. Geneva: World Health Organization, 2011.
［9］Sullivan EA，Kreiswirth BN，Palumbo L，et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City．Lancet，1995，345(8958)：1148-1150．
［10］肖和平.耐多药结核病化疗药物的选择与方案的制定.中华结核和呼吸杂志，2006,29(8):517-519.
［11］World Health Organization. Guidelines for the programmaticmanagement of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: World Health Organization, 2006.
［12］吴惠忠，尹建军，钟耐容，等. 广东省全球基金耐多药结核病项目阶段性实施情况分析.中国防痨杂志, 2013,35(10): 799-802.
［13］唐神结，肖和平. 利奈唑胺抗结核作用的研究及其最新进展. 中华临床医师杂志(电子版)，2010，4（1）：63-66．
［14］中国防痨协会结核病临床专业委员会.结核病临床诊治进展年度报告（2012年）（第二部分结核病临床治疗）.中国防痨杂志,2013,35(7):488-510.
［15］Nuermberger EL，Spigelman MK，Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology,2010,15(5)：764-778.
［16］Ma Z，Lienhardt C，McIlleron H，et al．Global tuberculosis drug development pipeline: the need and the reality.Lancet，2010，375（9731）：2100-2009.
［17］Diacon AH，Donald PR，Pym A，et al．Randomized pilot trial of eight weeks of bedaquiline（TMC207） treatment for multidrug-resistant tuberculosis：long-term outcome，tolerability，and effect on emergence of drug resistance. Antimicrob Agents Chemother,2012,56(6):3271-3276.
［18］Gler MT，Skripconoka V，Sanchez-Garavito E，et al．Delamanid for multidrug-resistant pulmonary tuberculosis．N Engl J Med, 2012, 366(23):2151-2160．
［19］Skripconoka V，Danilovits M，Pehme L，et al．Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J,2013，41(6)：1393-1400．
［20］World Health Organization.Joint meeting of the global GLC Committee and the MDR-TB Core Group.Geneva: World Health Organization, 2013.
［21］Cox H，Ford N．Linezolid for the treatment of complicated drug-resistant tuberculosis：a systematic review and meta ana-lysis．Int J Tuberc Lung Dis，2012，16（4）:447-454．
［22］Rosenthal IM,Zhang M，Williams KN，et al．Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med, 2007,4(12):e344．

[1]	邱勇, 权卓, 屈榕, 田发君, 李蒙, 王更生, 王娅, 郭明成, 高谦. 县级实验室结核病检测方法的诊断效果分析: 一项基于真实世界数据的回顾性研究[J]. 中国防痨杂志, 2025, 47(2): 181-188.
[2]	李杨, 孙峰, 张文宏. 结核病短程治疗研究:回顾与展望[J]. 中国防痨杂志, 2024, 46(9): 991-997.
[3]	李琦, 聂文娟, 初乃惠. 耐药肺结核短程治疗方案面临的困难与挑战[J]. 中国防痨杂志, 2024, 46(11): 1297-1302.
[4]	王雪钰, 石文卉, 李琦, 荆玮, 初乃惠, 聂文娟. 百地滋阴丸和参芪益肺丸辅助治疗敏感肺结核患者有效性和安全性:一项全国随机对照多中心临床研究[J]. 中国防痨杂志, 2024, 46(11): 1306-1312.
[5]	付亮, 邓国防. MDR-Chin研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景[J]. 中国防痨杂志, 2024, 46(1): 18-22.
[6]	赵嘉文, 张永忠, 李振华, 毛毅铖, 张菁菁, 胡成洋, 张秀军, 阚晓红. 安徽省三市大气污染物和绿地暴露对初治结核病患者病亡率的影响[J]. 中国防痨杂志, 2024, 46(1): 75-84.
[7]	丁芹, 陈薇, 张胜康, 任斐, 陈晓红, 胡春梅, 陈丹萍, 范琳. 肺外结核患者的营养状况调查及影响因素分析[J]. 中国防痨杂志, 2023, 45(9): 839-844.
[8]	丁芹, 张胜康, 任斐, 陈晓红, 胡春梅, 陈薇, 范琳. 耐药肺结核患者的营养状况调查及影响因素分析:一项多中心、大样本研究[J]. 中国防痨杂志, 2023, 45(9): 826-832.
[9]	吴塔娜, 李玉红, 刘小秋. 依托基本公共卫生服务对老年人开展肺结核主动筛查策略的可行性研究[J]. 中国防痨杂志, 2023, 45(4): 372-376.
[10]	周奉, 李同心, 杨松, 唐神结. 结核病短程治疗方案的研究进展[J]. 中国防痨杂志, 2023, 45(3): 311-317.
[11]	戈启萍, 张立杰, 黄学锐, 姜广路, 韩喜琴, 王敬萍, 杜建, 马艳, 高微微. 首次复治敏感肺结核治疗新方案疗效的验证性研究[J]. 中国防痨杂志, 2023, 45(11): 1078-1083.
[12]	高丹, 王玲华, 黄金鹏, 张玥, 毛潇潇. 结核性脓胸行胸腔镜清除术患者中西医结合肺康复护理方案的应用效果分析[J]. 中国防痨杂志, 2023, 45(10): 940-948.
[13]	高丹, 王玲华, 黄金鹏, 张玥, 毛潇潇. 结核性脓胸行胸腔镜清除术患者中西医结合肺康复护理方案构建[J]. 中国防痨杂志, 2023, 45(10): 932-939.
[14]	谢静仪, 邹瑞丰, 陈玉兰, 陈永, 刘冬舟, 洪小平. 系统性红斑狼疮合并结核感染临床特征及外周血淋巴细胞亚群分析[J]. 中国防痨杂志, 2022, 44(9): 911-916.
[15]	王玉香, 陈秋奇, 余鑫鑫, 詹森林, 张培泽, 邓国防. 3HP方案治疗风湿性疾病合并结核分枝杆菌潜伏感染的前瞻性研究[J]. 中国防痨杂志, 2022, 44(9): 906-910.

耐药结核病化学治疗研究的过去、现状与未来

The past, present and future of study in the chemotherapy of drug-resistant tuberculosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

友情链接